Eikon Therapeutics(EIKN.US)登陆纳斯达克 开盘跌超5%

Core Viewpoint - Eikon Therapeutics has made its debut on NASDAQ with an opening drop of over 5%, trading at $17.05, below its IPO price of $18 [1] Company Overview - Eikon Therapeutics was founded in 2019 by Nobel Prize winners Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian [1] - The company is focused on developing multiple experimental cancer therapies [1] Clinical Development - The most advanced candidate drug, EIK1001, is undergoing a mid-to-late stage clinical trial for skin cancer in collaboration with Merck's Keytruda [1] - Interim analysis data for this study is expected to be released in the second half of 2026 [1]